Jack Lawler Ph.D. is Professor of Pathology at Harvard Medical School and Director of Experimental Pathology at the Beth Israel Deaconess Medical Center, Boston, Mass. Additionally, Dr. Lawler is Co-Director of the Training Grant in Angiogenesis and Inflammation in the Department of Pathology at the Beth Israel Deaconess Medical Center and is the Leader of the Angiogenesis, Invasion and Metastasis Discipline-based Working Group of the Dana Farber/Harvard Cancer Center.

Dr. Lawler received his B.S. in Physics from Villanova University in 1971 and his Ph.D. in Physics from Boston College in 1976. He was a post-doctoral fellow at the Dana Farber Cancer Institute in the Structural Biology Laboratory where he performed the first purification and biochemical characterization of thrombospondin-1. In 1982, Dr. Lawler became Assistant Professor in the Department of Medicine at Tufts University Medical School and St. Elizabeth’s Hospital, Boston. While Dr. Lawler was a Visiting Scientist in Richard Hynes’ lab at MIT, he cloned and sequenced thrombospondin-1 and engineered the thrombospondin-1-null mouse. In 1988, Dr. Lawler became Associate Professor of Pathology at Harvard Medical School and Brigham and Women’s Hospital. He has published over 200 articles and co-authored the book “The Thrombospondin Gene Family”. Dr. Lawler has also served on the editorial boards of the Journal of Cellular and Molecular Medicine, Current Drug Targets, Journal of Cell Communication and Signaling, and Discoveries. The NIH has continuously supported his work for three decades.